Selecta Biosciences Presents Full Data from Phase 2 Trial of SEL-212 for Chronic Refractory Gout at EULAR 2019
12 juin 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Present at the Jefferies Healthcare Conference on June 06, 2019
30 mai 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
Selecta Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update
09 mai 2019 08h00 HE
|
Selecta Biosciences, Inc.
- Patient enrollment ongoing in COMPARE trial evaluating efficacy and safety of SEL-212 vs. KRYSTEXXA® in patients with chronic refractory gout; interim data expected in 4Q19 - - Preclinical data...
Selecta Biosciences to Announce Date of First Quarter 2019 Financial Results Conference Call
02 mai 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
16 avr. 2019 16h05 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Present at the Needham & Company 18th Annual Healthcare Conference April 9, 2019
02 avr. 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team
29 mars 2019 08h00 HE
|
Selecta Biosciences, Inc.
-First patient enrolled in COMPARE trial evaluating efficacy and safety of SEL-212 v. KRYSTEXXA® in patients with chronic refractory gout-Strengthened management and clinical teams with the...
Selecta Biosciences Announces New Employment Inducement Grant
26 mars 2019 16h05 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
Selecta Biosciences Announces Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update
15 mars 2019 08h00 HE
|
Selecta Biosciences, Inc.
Phase 2 head-to-head (COMPARE) clinical trial of SEL-212 vs. KRYSTEXXA® to begin in 1Q19, interim six-month data expected in 4Q19Collaboration with CureCN projected to dose first patient with...
Selecta Biosciences to Report Fourth Quarter and Year End 2018 Financial Results and Provide Corporate Update
08 mars 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...